Scientific Programme




Topics and Highlights


Ge-68/Ga-68 generators: Current developments and future directions


  • Theory and practice of generator post-processing
  • Automation in generator elution and labelling including GMP aspects
  • Specific activities, dosimetry, breakthrough, waste
  • New ligands for Ga-68
  • Chemistry of new Ga-68 labelled tracers
  • Quality control of Ga-68 and Lu-177-labelled DOTA-octreotides
  • Post-processing of Ga-68 generator eluates
  • Regulatory issues related to investigational radiopharmaceuticals
  • Large scale production of therapeutic radionuclides (Lu-177, Y-90 and other trivalent therapeutic radiometals)
  • Chemistry of new Lu-177 labelled tracers
  • Pre-clinical evaluation of new Lu-177 tracers
  • Dosimetry and RadiationProtection - Practical issues


Ga-68 molecular imaging – A worldwide experience 


  • Ga-68 for imaging bone metastases
  • Ga-68 for infection imaging
  • Ga-68-labeled PET tracers for studying pathophysiological properties of the P-glycoprotein
  • Ga-68 in clinical practice - new tracers and new indications
  • Current progress and novel developments in ongoing research projects
  • Ga-68-labelled tracers for therapy planning of PSMA binding endoradiotherapeutics
  • Targeted radionuclide therapy in the context of other systemic therapy for neuroendocrine tumors – Where we stand in 2013
  • Multi-modality molecular imaging - Strengths and Challenges


Milestones in NET management


Peptide Receptor Radionuclide Therapy (PRRNT) 


  • PRRNT – Worldwide clinical experience
  • Milestones of PRRNT - clinical applications and future developments
  • Selection criteria for PRRNT
  • Diagnosis and Follow-up after PRRNT using Receptor-PET/CT
  • The importance of quantitative molecular imaging and automated image analysis 
  • Dosimetry and radiation protection - Practical issues
  • THERANOSTICS: From molecular imaging using Ga-68 labeled tracers and PET/CT to personalized therapy


Surgical options


  • Personalized approach to NET surgery - organ bank to immunohistochemisty and molecular imaging
  • Current status of surgical options in management of NET patients


Targeted tumor therapy with Alpha Emitters 


  • Production of alpha emitters
  • Principles of Alpha-Immunotherapy
  • Treatmentof  bladder cancer with Bi-213-anti-EGFR immunoconjugates in a nude mouse model
  • Pre-clinical and clinical studies with alpha emitters
  • Production of the alpha emitters Ac-225 / Bi-213 and their application in peptide receptor alpha therapy of neuroendocrine and brain tumors
  • Targeted Alpha Particle Therapy for Acute Myeloid Leukemia
  • Dosimetry for alpha-emitter therapy: Approach to Treatment Planning


Pre-Clincal / Clinical Molecular Imaging: Translational Relevance


  • Pre-clinical evaluation of new Ga-68 tracers
  • Ga-68-Metalloprobes for Biomedical Imaging
  • Ga-68 Labeled Genomic Biomarkers for PEM Imaging of Breast Cancer.
  • MolecularImaging (SPECT/PET/CT) in Drug Development
  • Translational Relevance of  the Pre-Clinical Molecular Imaging  in  the development of  SPECT/PET probes for the early detection ofhuman cancers   
  • Molecular imaging of multiple myeloma
  • Radio-labelling strategies of stem cells
  • Translational Relevance of  Preclinical Tracking / Homing of radiolabeled stemcells in the development of  stemcell therapeutics in different clinical situations
  • Genomics and Proteomics Profiling to Cancers: Leading to Personalized Medicine
  • Genomoc biomarkers for molecular imaging: Predicting the future
  • Genome to Systems Strategies Enabling Route to Personalized Medicine
  • Novel radiochemical separation of arsenic from selenium for 72Se/72As generator
  • A Bridge Not Too far: Personalized Medicine with the Use of Theranostic Radiopharmaceuticals



Note: We are planning to have Free Oral / Poster Presentations.

There will be ample space and opportunity for discussions during the meeting